Making A Difference for Your AD Patients: Patient-Centric Strategies to Improve Their Care - Pediatric Patient

Released On
January 31, 2022

Expires On
January 31, 2023

Media Type
Internet

Completion Time
45 minutes

Specialty
Dermatologists, allergists, immunologists, other specialists (MD/DOs), and nurse practitioners, physician assistants

Topic(s)
Atopic dermatitis, shared decision-making, biologic therapy

Scroll to the Bottom of this Information to Begin this Course

This educational activity is provided by Horizon CME.

This activity is supported by an independent education grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)
  • Nurses — 0.75 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

Dermatologists, allergists, immunologists, other specialists (MD/DOs), and nurse practitioners, physician assistants

Program Overview

This engaging and clinically relevant learning design system will improve your skills in assessing and treating pediatric patients with atopic dermatitis and establish the importance of personalized and individualized care to optimize outcomes.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe optimal shared decision-making strategies to effectively engage patients/caregivers
  • Integrate patient/caregiver preferences into guideline-recommended treatment decisions
  • Tailor atopic dermatitis therapy for patients whose symptoms are poorly managed by current treatment

 

Faculty

Robert Sidbury, MD, MPH

Chief, Division of Dermatology
Seattle Children’s Hospital
Professor, Department of Pediatrics
University of Washington School of Medicine
Seattle, WA

Steven R. Feldman, MD, PhD

Department of Dermatology
Wake Forest School of Medicine
Winston-Salem, NC

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

 

Credit Designation

Horizon CME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learner Assurance Statement

Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.

Faculty Disclosures

Robert Sidbury, MD, MPH
  • Advisory Boards: Leo Pharma
  • Contracted Research: Regeneron, Galderma, Pfizer, and Castle
Steven Feldman, MD, PhD
  • Consultant: Abbvie, Janssen, Alvotech, vTv, BMS, Samsung, Pfizer, Boehringer, Dermavant, Arcutis, Novartis, UCB, Helsinn, Sun, Almirall, Leo, Mylan, Forte, Arena, Biocon, Accordant, Argenx, and Sanofi
  • Speaker: Lilly, Abbvie, Janssen, Alvotech, Amgen, Sun, Sanofi, and Regeneron
  • Research Funding: Lilly Abbvie, janssen, Pfizer, UCB, Almirall, and Galderma

Planner Disclosures

Those involved in the planning of this activity disclosed no financial relationships with an ACCME defined ineligible company within the past 24 months.

Other Contributor Disclosures

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no financial relationships with an ACCME defined ineligible company within the past 24 months.

How to Claim Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.75 AMA PRA Category 1 Credits™. A statement of credit will be available to print from your user history page.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Statement of Independence

Per ACCME, AMA and FDA regulations, it is understood that commercial supporters will have no influence on the content of the activity. Horizon CME will ensure an unbiased presentation and provide full disclosure of relationships between Horizon CME and all commercial supporters and any significant financial interest or other relationship between faculty and manufacturers of commercial products discussed in the activities. It is understood that commercial support funding of this activity is not in any way conditioned upon any present or future business relationship.

Commercial Support

This activity is supported by an independent education grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Copyright © 2022 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.